ANDA 75804, held by Barr. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 75804 (Sprintec), held by Barr, was first approved by FDA on Sep 25, 2002, with 6 approved supplements and 0 published complete response letters.
Sprintec is a combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sprintec0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 36Labeling · Standard review | Approved | None posted |
| Jan 28, 2022 | Supplement 30Labeling · Standard review | Approved | None posted |
| Apr 13, 2016 | Supplement 26Labeling · Standard review | Approved | None posted |
| Apr 13, 2016 | Supplement 27Labeling · Standard review | Approved | None posted |
| Jan 31, 2013 | Supplement 25Labeling · Standard review | Approved | None posted |
| Aug 31, 2011 | Supplement 23Labeling | Approved | None posted |
| Sep 25, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters